Niaspan niacin: Additional Phase III data

The double-blind, North American Phase III AIM-HIGH trial in 3,414 patients showed that high doses of daily extended-release Niaspan plus Zocor simvastatin missed the primary endpoint of significantly reducing a composite of death from

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE